Senseonics (NYSE:SENS) today reported first-quarter financial results that exceeded Wall Street’s revenue expectations.
However, shares of SENS ticked up 1.4% to $5.43 apiece in post-market trading today as the company reported recent advances with its diabetes technology and increased its guidance.
The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $32.3 million on sales of $11.7 million for the three months ended March 31, 2026.
Senseonics recorded a more than $18 million bottom-line slide. However, sales increased by 87.1% during the same period a year ago.
Losses per share came in at 71¢, landing 1¢ behind expectations on Wall Street. Sales came in ahead of estimates, though, as experts forecast $9.8 million in revenue.
Senseonics now expects full-year revenue of between approximately $60 million and $64 million. That would mark year-over-year growth of 70%-82%, based on growing scale and the expected completion of the transition of Eversense commercialization from Ascensia in Europe to bring the entire sales and marketing infrastructure in-house.
The company previously projected sales between $58 million and $62 million. It expects continued boosts from the launch of Eversense 365 in Europe and the recent raise of $100 million in equity and debt financing to support its commercial strategy and pipeline.
Tim Goodnow, president and CEO of Senseonics, said:
“This was our first quarter as a fully-integrated commercial organization in the U.S., following the successful transition of the U.S. Eversense Sales and Marketing team to Senseonics. However, this wasn’t just a quarter of important strategic progress, it was a strong quarter of commercial delivery, with both revenue and gross margins exceeding our expectations. We have now secured over $100 million in equity and debt financing to continue to fund our ongoing global launch of Eversense 365 and support the continued development of our pipeline, which includes the Gemini and Freedom systems. I’m proud of the team’s ability to both adapt and deliver during a crucial evolution of our business, which is now end-to-end, gaining momentum and moving forward more ambitiously.”
The analysts’ take
BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber maintain a “Neutral” rating for Senseonics. They said the company moved “fast off the blocks” with its performance after taking over control of commercial activity.
The analysts say the buildout of the company’s in-house commercial capabilities underpinned its guidance increase, reflecting management’s view of the pace of its Eversense 365 rollout outside the U.S., alongside direct-to-consumer efforts and spending.
“We applaud [Senseonics] on its strong start to the year but keeping in mind the company’s history of lumpy commercial results, we await more evidence of consistent growth, accelerating adoption, and also want to see spending better controlled. With this in mind, we maintain our Neutral rating,” the analysts wrote.
